Key facts
- This page summarizes Hyam Levitsky's Form 4 filing for Century Therapeutics, Inc. (IPSC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Mar 2024, 19:34.
Hyam Levitsky - 07 Mar 2024 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)
- Reporting relationship
- President of R&D
- Issuer ticker
- IPSC
- Reported as of
- 07 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Mar 2024, 19:34:28 UTC
- Prior SEC filing
- 14 Apr 2023
- Next SEC filing
- 03 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Douglas Carr, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Hyam Levitsky filed Form 4 for Century Therapeutics, Inc. (IPSC) on 11 Mar 2024.
Change
- Previous filing in this sequence was filed on 14 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IPSC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +24,000
- Change %
- Price
- $0.000000
- Shares after
- 24,000
- Date
- 07 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
IPSC
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 536,544
- Date
- 07 Mar 2024
- Ownership
- By Irrevocable Spousal Trust for Rhonda L. Zuckerman
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IPSC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +146,000
- Change %
- Price
- $0.000000
- Shares after
- 146,000
- Date
- 07 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 146,000
- Exercise price
- $5.32
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.
Footnote F2
The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.
SEC remarks
Exhibit 24 - Power of Attorney